Noxopharm Limited (ASX:NOX)

Noxopharm Ratios and Metrics

Market cap in millions AUD. Fiscal year is July - June.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr 16, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Market Capitalization	23	16	19	13	57	186
Market Cap Growth	-12.39%	-18.18%	53.49%	-77.95%	-69.35%	428.46%
Enterprise Value	27	12	14	1	41	167
Last Close Price	0.07	0.05	0.07	0.04	0.20	0.65
PS Ratio	6.79	5.59	8.04	2.09	10.50	33.15
PB Ratio	-20.44	22.87	3.51	1.39	2.36	4.56
P/TBV Ratio	-	22.87	3.51	1.39	2.36	4.56
EV/Sales Ratio	8.01	4.11	5.89	0.24	7.48	29.85
Debt / Equity Ratio	-3.77	3.59	-	-	0.01	0.01
Net Debt / Equity Ratio	-3.68	1.34	-0.42	-0.33	-0.57	-0.65
Net Debt / EBITDA Ratio	-0.94	-0.17	0.50	0.29	1.46	1.85
Net Debt / FCF Ratio	-0.57	-0.16	3.39	0.28	1.01	2.99
Asset Turnover	0.67	0.50	0.28	0.33	0.15	0.17
Inventory Turnover	-	-	-	-	10.67	30.24
Quick Ratio	0.80	1.16	3.79	9.45	8.43	4.79
Current Ratio	0.81	1.18	3.83	9.52	9.13	4.84
Return on Equity (ROE)	-343.56%	-157.93%	-49.12%	-90.72%	-57.53%	-34.84%
Return on Assets (ROA)	-54.04%	-59.24%	-34.01%	-36.23%	-16.42%	-26.86%
Return on Capital Employed (ROCE)	397.80%	-757.40%	-83.10%	-116.10%	-40.20%	-35.60%
Earnings Yield	-23.82%	-30.95%	-18.55%	-119.82%	-32.76%	-5.03%
FCF Yield	-	-36.91%	-3.55%	-87.11%	-24.10%	-4.76%
Buyback Yield / Dilution	-	-	-	-0.35%	-10.37%	-90.70%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.